@article{cba9df0262544c5bbed885a4eb45f3bc,
title = "The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives",
abstract = "The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.",
keywords = "Alzheimer's disease, MRI, PET, Tau, amyloid, biomarkers, cerebrospinal fluid, cognitive impairment, neuroimaging",
author = "Weber, {Christopher J.} and Carrillo, {Maria C.} and William Jagust and Jack, {Clifford R.} and Shaw, {Leslie M.} and Trojanowski, {John Q.} and Saykin, {Andrew J.} and Beckett, {Laurel A.} and Cyrille Sur and Rao, {Naren P.} and Mendez, {Patricio Chrem} and Black, {Sandra E.} and Kuncheng Li and Takeshi Iwatsubo and Chang, {Chiung Chih} and Sosa, {Ana Luisa} and Rowe, {Christopher C.} and Perrin, {Richard J.} and Morris, {John C.} and Healan, {Amanda M.B.} and Hall, {Stephen E.} and Weiner, {Michael W.}",
note = "Funding Information: The Clinical core has identified demographic gaps in the ADNI‐3 cohort. Currently only 14% of ADNI‐3 participants identify as racial or ethnic minorities. Most identify as Caucasian and >90% have a 4‐year college education. This spurred formation of a Diversity Taskforce within WW‐ADNI. ADNI‐4 will employ targeted recruitment strategies, supported by dedicated funding for Black and Latinx participants and recruiters. These efforts will also focus on AD enrollment. Competition with treatment trials significantly impacted AD participant enrollment in ADNI‐3. Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",
year = "2021",
doi = "10.1002/trc2.12226",
language = "English (US)",
volume = "7",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",
number = "1",
}